In the latest trading session, 0.62 million Rallybio Corp (NASDAQ:RLYB) shares changed hands as the company’s beta touched -0.93. With the company’s most recent per share price at $0.26 changed hands at -$0.16 or -38.81% at last look, the market valuation stands at $10.82M. RLYB’s current price is a discount, trading about -1230.77% off its 52-week high of $3.46. The share price had its 52-week low at $0.42, which suggests the last value was -61.54% down since then. When we look at Rallybio Corp’s average trading volume, we note the 10-day average is 61870.0 shares, with the 3-month average coming to 58.77K.
Analysts gave the Rallybio Corp (RLYB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RLYB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Rallybio Corp’s EPS for the current quarter is expected to be -0.29.
Rallybio Corp (NASDAQ:RLYB) trade information
Instantly RLYB was in red as seen in intraday trades today. With action -57.38%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -72.92%, with the 5-day performance at -57.38% in the red. However, in the 30-day time frame, Rallybio Corp (NASDAQ:RLYB) is -61.00% down. Looking at the short shares, we see there were 0.34 million shares sold at short interest cover period of 6.64 days.
Rallybio Corp (RLYB) estimates and forecasts
Year-over-year growth is forecast to reach -100.00% down from the last financial year.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at -100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -19.41%. The 2025 estimates are for Rallybio Corp earnings to decrease by -1.20%, but the outlook for the next 5-year period is at 11.24% per year.
Rallybio Corp (NASDAQ:RLYB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.04% of Rallybio Corp shares while 77.08% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 80.32%. There are 77.08% institutions holding the Rallybio Corp stock share, with VIKING GLOBAL INVESTORS LP the top institutional holder. As of 2024-06-30, the company held 10.288% of the shares, roughly 4.19 million RLYB shares worth $5.62 million.
JOHNSON & JOHNSON holds the second largest percentage of outstanding shares, with 8.9184% or 3.64 million shares worth $4.87 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were abrdn Healthcare Investors and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. With 755.08 shares estimated at $0.19 million under it, the former controlled 1.81% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.53% of the shares, roughly 636.28 shares worth around $0.16 million.
